康方生物(09926.HK)自主研發藥物AK109中國首例晚期實體瘤患者完成入組及給藥
格隆匯 6 月 17日丨康方生物-B(09926.HK)發佈公告,公司自主研發的VEGFR-2新型全人源化單克隆抗體藥物AK109在中國劑量爬坡I期臨牀試驗中,首例晚期實體瘤患者已經順利完成入組及給藥。此研究由浙江大學醫學院附屬第一醫院牽頭並由其腫瘤內科主任徐農教授作為主要研究者。
AK109同靶點藥物Cyramza(雷莫蘆單抗)在2018年實現了8.21億美元的銷售額,印證了其廣闊的市場前景。公司計劃進一步開展AK109與公司雙特異性抗體AK104 (PD-1/CTLA-4)或公司的單克隆抗體penpulimab (AK105, PD-1)的藥物聯用臨牀試驗,以評估其治療肝癌的療效和安全性。
AK109是公司自主研發的VEGFR-2新型全人源化單克隆抗體藥物,可用於治療多種惡性腫瘤。AK109不具有ADCC活性,能夠高親和力地與人VEGFR-2蛋白特異性結合,阻斷VEGF與VEGFR-2的結合,有效抑制VEGF/VEGFR-2結合所誘導的血管內皮細胞增殖,從而干擾腫瘤新生血管形成,抑制腫瘤的發生及發展,公司未來將積極探索AK109與公司產品線中其他藥物聯合療法的相關研究。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.